Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Izokibep Phase 2 in Active Psoriatic Arthritis
NCT04713072Phase 2Completed
- Sponsor
- Acelyrin
- Start
- Aug 2020
- Primary completion
- Oct 2021
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of izokibep in psoriatic arthritis (PsA) (3 arms), sponsored by Acelyrin. Primary endpoint: American College of Rheumatology 50 response rate at 16 weeks. Started Aug 2020; status: completed.
02
Drugs
izokibep
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04713072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04713072.